<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04160338</url>
  </required_header>
  <id_info>
    <org_study_id>corneal collagen cross linking</org_study_id>
    <nct_id>NCT04160338</nct_id>
  </id_info>
  <brief_title>Assessment of Corneal Endothelium After Collagen Cross Linking</brief_title>
  <acronym>CXL</acronym>
  <official_title>A Specular Microscopic Study of Corneal Endothelium After Accelerated Corneal Collagen Cross Linking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effect of accelerated corneal collagen cross linking
      on corneal endothelium using the specular microscopy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Keratoconus (KC) is a progressive, non-inflammatory corneal degenerative disease. It is a
      pathology characterized by a progressive thinning and protrusion of the cornea that ends in a
      cone‚Äêshaped cornea. This results in progressive myopia and irregular astigmatism with
      associated progressive loss of vision and thus reduced quality of life.Collagen cross-linking
      (CXL) is a relatively new conservative approach for progressive corneal ectasia. The main
      indication for CXL is to slow the progression of corneal ectatic diseases, such as
      keratoconus, pellucid marginal degeneration (PMD), keratoglobus and iatrogenic ectasia.The
      basic principle of this method is the chemical interaction of ultraviolet A radiation
      (315-400nm ) and riboflavin to induce covalent bond formation between collagen fibers of the
      cornea. In this way, the stiffness and rigidity of the cornea are provided.Corneal collagen
      cross-linking (CXL) was first introduced by Wollensak with an ultraviolet-A (UVA) protocol of
      3 medium wave mW/cm2 intensity at 370 nm over an exposure time of 30 minutes (now termed the
      &quot;Dresden protocol&quot;). Researchers have proposed accelerated CXL (ACXL) protocols, to improve
      convenience and comfort for patients. These ACXL protocols have the aim of decreasing UVA
      exposure time by increasing UVA fluency to achieve the same overall total UVA dosage.Despite
      corneal CXL is a safe and effective procedure with few known side effects .Persistent corneal
      edema and possible endothelial cell damage have been reported in a few cases after CXL. Based
      on the extent of endothelial damage, patients may require penetrating keratoplasty.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial cell count by specular microscopy.</measure>
    <time_frame>from preoperatively to 6 months postoperatively</time_frame>
    <description>specular microscopy will be used to assess corneal endothelial cell count after accelerated corneal collagen cross linking</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endothelial cell morphology by specular microscopy.</measure>
    <time_frame>from preoperatively to 6 months postoperatively</time_frame>
    <description>specular microscopy will be used to assess corneal endothelial cell morphology after accelerated corneal collagen cross linking</description>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Accelerated Corneal Collagen Cross Linking</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>specular microscopy</intervention_name>
    <description>An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo specular microscopic examination of corneal endothelium before CXL procedure.
Patients will be assigned to undergo accelerated (epithelium-off ,transepithelial ) CXL .
Follow up specular microscopy will be done 3 months and 6 months after corneal collagen cross linking procedure .</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who underwent accelerated corneal collagen cross linking
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. patients with mild to moderate corneal ectasia who are candidates for CXL.

        Exclusion Criteria:

          1. patients with advanced corneal ectasia with maximum keratometry readings &lt;56 diopters.

          2. corneal pachymetry &gt;380um.

          3. corneal scarring.

          4. previous corneal surgeries (e.g intrastromal corneal ring segments)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed T Abdelmonem, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Assiut Uneversity</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hazem A Hazem, lecturer</last_name>
    <role>Study Director</role>
    <affiliation>Assiut Uneversity</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmoud A Abdelsalam, lecturer</last_name>
    <role>Study Director</role>
    <affiliation>Assiut Uneversity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naglaa MA Abdelmohsen, M.B.B.CH.</last_name>
    <phone>+201095459579</phone>
    <email>dr.naglaa15@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008 May;34(5):796-801. doi: 10.1016/j.jcrs.2007.12.039.</citation>
    <PMID>18471635</PMID>
  </reference>
  <reference>
    <citation>Subasinghe SK, Ogbuehi KC, Dias GJ. Current perspectives on corneal collagen crosslinking (CXL). Graefes Arch Clin Exp Ophthalmol. 2018 Aug;256(8):1363-1384. doi: 10.1007/s00417-018-3966-0. Epub 2018 Apr 6. Review.</citation>
    <PMID>29623463</PMID>
  </reference>
  <reference>
    <citation>Mencucci R, Marini M, Paladini I, Sarchielli E, Sgambati E, Menchini U, Vannelli GB. Effects of riboflavin/UVA corneal cross-linking on keratocytes and collagen fibres in human cornea. Clin Exp Ophthalmol. 2010 Jan;38(1):49-56. doi: 10.1111/j.1442-9071.2010.02207.x.</citation>
    <PMID>20447101</PMID>
  </reference>
  <reference>
    <citation>Wen D, Li Q, Song B, Tu R, Wang Q, O'Brart DPS, McAlinden C, Huang J. Comparison of Standard Versus Accelerated Corneal Collagen Cross-Linking for Keratoconus: A Meta-Analysis. Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):3920-3931. doi: 10.1167/iovs.18-24656.</citation>
    <PMID>30073363</PMID>
  </reference>
  <reference>
    <citation>Kirgiz A, Eliacik M, Yildirim Y. Different accelerated corneal collagen cross-linking treatment modalities in progressive keratoconus. Eye Vis (Lond). 2019 Jun 3;6:16. doi: 10.1186/s40662-019-0141-6. eCollection 2019.</citation>
    <PMID>31172016</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Zhao J, Li M, Tian M, Shen Y, Zhou X. Conventional and transepithelial corneal cross-linking for patients with keratoconus. PLoS One. 2018 Apr 5;13(4):e0195105. doi: 10.1371/journal.pone.0195105. eCollection 2018.</citation>
    <PMID>29621306</PMID>
  </reference>
  <reference>
    <citation>Vazirani J, Bagga B, Taneja M. Persistent corneal edema after collagen cross-linking for keratoconus. Am J Ophthalmol. 2013 Apr;155(4):775. doi: 10.1016/j.ajo.2013.01.003.</citation>
    <PMID>23521904</PMID>
  </reference>
  <reference>
    <citation>Sedaghat M, Bagheri M, Ghavami S, Bamdad S. Changes in corneal topography and biomechanical properties after collagen cross linking for keratoconus: 1-year results. Middle East Afr J Ophthalmol. 2015 Apr-Jun;22(2):212-9. doi: 10.4103/0974-9233.151877.</citation>
    <PMID>25949080</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Naglaa Mostafa Abdelhafez Abdelmohsen</investigator_full_name>
    <investigator_title>resident doctor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

